製品名Anti-Metabotropic Glutamate Receptor 4 antibody
Metabotropic Glutamate Receptor 4 一次抗体 製品一覧
製品の詳細Rabbit polyclonal to Metabotropic Glutamate Receptor 4
アプリケーション適用あり: ICC/IF, IHC-P, IHC-Fr, WB, ELISAmore details
種交差性交差種: Mouse, Rat, Chicken, Cat, Human
Synthetic peptide derived from human Metabotropic Glutamate Receptor 4 (C-terminal)
- 293 cell extracts.
保存方法Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C.
Preservative: 0.02% Sodium azide
Constituents: 0.87% Sodium chloride, 50% Glycerol, PBS
Without Mg+2 and Ca+2
Concentration information loading...
精製度Immunogen affinity purified
Our Abpromise guarantee covers the use of ab53088 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ICC/IF||Use a concentration of 5 µg/ml.|
|IHC-P||Use a concentration of 2 µg/ml. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.|
|WB||1/500 - 1/1000. Detects a band of approximately 102 kDa (predicted molecular weight: 102 kDa).|
機能Receptor for glutamate. The activity of this receptor is mediated by a G-protein that inhibits adenylate cyclase activity.
組織特異性Strongly expressed in the cerebellum. Expressed at low levels in hippocampus, hypothalamus and thalamus. No expression detected in liver.
配列類似性Belongs to the G-protein coupled receptor 3 family.
- Information by UniProt
- Glutamate receptor metabotropic 4 antibody
- GPRC1D antibody
- Grm4 antibody
Ab53088 staining Human cerebellum. Staining is localised to the cell membrane.
Left panel: with primary antibody at 2 ug/ml. Right panel: isotype control.
Sections were stained using an automated system DAKO Autostainer Plus , at room temperature. Sections were rehydrated and antigen retrieved with the DAKO 3-in-1 antigen retrieval buffer EDTA pH 9.0 in a DAKO PT Link. Slides were peroxidase blocked in 3% H2O2 in methanol for 10 minutes. They were then blocked with Dako Protein block for 10 minutes (containing casein 0.25% in PBS) then incubated with primary antibody for 20 minutes and detected with Dako Envision Flex amplification kit for 30 minutes. Colorimetric detection was completed with diaminobenzidine for 5 minutes. Slides were counterstained with Haematoxylin and coverslipped under DePeX. Please note that for manual staining we recommend to optimize the primary antibody concentration and incubation time (overnight incubation), and amplification may be required.
All lanes : Anti-Metabotropic Glutamate Receptor 4 antibody (ab53088) at 1/500 dilution
Lane 1 : 293 cell extracts, treated
with Forskolin (40nM, 30mins)
Lane 2 : 293 cell extracts, treated
with Forskolin (40nM, 30mins) with peptide
Predicted band size: 102 kDa
Observed band size: 102 kDa
ab53088 staining the Metabotropic Glutamate Receptor 4 in Rat heart tissue sections by IHC-Fr (frozen sections). Tissue was fixed with paraformaldehyde, permeabilized with 1% Triton and blocked with 3% serum for 2 hours at 20°C. Samples were incubated with primary antibody (1/200) for 12 hours at 4°C. An HRP-conjugated goat anti-rabbit IgG polyclonal (1/400) was used as the secondary antibody.
ICC/IF image of ab53088 stained HepG2 cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab53088, 5µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
This product has been referenced in:
- Novati A et al. Environment-dependent striatal gene expression in the BACHD rat model for Huntington disease. Sci Rep 8:5803 (2018). Read more (PubMed: 29643462) »
- Jenkins BG et al. Functional modulation of G-protein coupled receptors during Parkinson disease-like neurodegeneration. Neuropharmacology 108:462-73 (2016). Read more (PubMed: 26581500) »